valu usd unless otherwis note
preview string strong quarterli result
like continu
view tougher comp make repeat organ growth
y/i difficult upsid consensu remain distinct possibl
segment could driver upsid
medic devic diagnost segment appear like
candid new product momentum libr alin rais
price target reiter outperform
estim ww revenu y/i cc ep
guidanc exclud fx
revenu growth estim segment cardiovascular
diagnost base current rate estim fx
bp headwind report revenu growth line abt forecast
contend sharp depreci argentinian
peso valu dollar term fell past month
medic devic growth approach match
busi unit within medic devic diabet
electrophysiolog structur heart three contribut
revenu estim medic devic year-
over-year growth medic devic revenu exclud fx
overcom sluggish growth even declin rhythm
manag vascular busi unit respect freestyl
libr specif estim ww sale y/i
ww sale y/i
expect manag narrow guidanc top half
previous commun rang earn call
increas forecast organ revenu growth bp
mid-point ep guidanc current guidanc
organ growth non-gaap ep
follow result expect narrow guidanc
organ growth non-gaap ep
revenu estim impli organ growth
ep estim consensu estim also
increas organ growth ep estim revis
estim cc growth bp higher prior estim
owe optimist view structur heart mitraclip diabet
libr diagnost howev bigger fx headwind leav
revenu estim unchang model organ
growth estim ep estim
due higher assumpt margin interest
incom consensu consensu price
target base blend ev/ebitda multipl
ebitda estim
price prior trade day market close estimate unless otherwis note
cours double-digit ep growth
product cycl refresh medic devic
diagnost cost synergi stj alr capit
deploy acceler debt repay push
abt revenu ep growth ahead sever med-tech
peer revenu estim impli
underli growth ep
estim repres growth given
momentum across four segment perceiv
upsid estim
freestyl libr repres major sourc upsid us
launch strong start growth
continu rapid pace us libr sale exceed
believ product us
alon next year libr alreadi approach
mark annual sale europ million
insulin user ww could adopt libr
shape excit year diagnost
well alr transact ad rapid diagnost
portfolio receiv fda approv first two
instrument new alin platform laboratori
diagnost other forthcom
come month alin suit gain good traction
europ five six instrument commerci
avail instrument drive high single-
nutrit
adult pediatr market
segment high-single-digit low-double-digit revenu
growth establish pharmaceut factor
drive organ revenu growth
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part analysi valu report segment individu
use respect ev/ebitda multipl blend ev/
ebitda multipl ebitda estim
billion yield target key assumpt underli
valuat cc revenu growth cc
growth basi point increas oper
margin year continu debt reduct
 price target impli price-to-earnings multipl
ep estim
arriv upsid scenario ev/ebitda multipl
ebitda estim billion key
differ base-cas assumpt cc
revenu growth basi point ebit
margin expans year due higher revenu growth
faster realiz cost synergi integr
stj alr capit deploy share repurchas
downsid scenario ebitda
billion key differ base-cas assumpt
mid-single-digit cc organ revenu growth
basi point ebit margin expans
year due slower revenu growth slower
realiz cost synergi
preview string strong quarterli result like continu
schedul report result wednesday octob host confer
call et forecast ww revenu billion non-gaap ep
septemb quarter consensu estim billion ww revenu
estim repres organ growth report growth includ fx
exclud rapid diagnost exhibit comparison organ revenu growth rate
respect case estim
higher revenu growth outsid intern exclud fx driven
nutrit diagnost cardiovascular neuromodul see potenti upsid
organ growth forecast come diagnost alin devic especi
structur heart diabet establish pharmaceut divis could also serv
sourc upsid
ww revenu estim segment follow growth rate cc
exhibit revenu model quarter
geographi worldwiderevenu revenu growth excl growth excl revenu growth excl growth revenu growth revenu excl revenu incl medic suppli devic
issu follow guidanc earn call
organ revenu growth mid-to high single-digit interpret
rapid diagnost sale million fx reduc revenu growth
guidanc produc rang billion report revenu
medic devic high single-digit interpret
nutrit mid-singl digit interpret
diagnost mid high single-digit interpret
epd mid high single-digit interpret
revenu growth medic devic segment approach
three highest growth busi unit within medic devic list order
revenu growth estim diabet electrophysiolog structur heart
three contribut revenu forecast medic devic
year-over-year growth medic devic revenu exclud fx refer
three busi unit contribut medic devic y/i growth
rhythm manag drag medic devic growth four
busi perform larg determin perform medic devic growth
forecast
exhibit revenu growth exclud fx variou busi unit compris medic devic segment
diabet experienc strong growth intern past sever
quarter due rapid uptak among consum freestyl libr feedback
american diabet associ annual meet june reveal great deal excit
libr well libr diabet ww sale
climb estim cc revenu growth diabet
growth estim could prove conserv
sale estim libr includ fx million billion billion
respect report earn call consum
use libr world-wide quit like figur cross one million coupl
month manag previous forecast
electrophysiolog structur heart
ww revenu growth electrophysiolog acceler four consecut quarter
approach growth spurt result sever new product
ensit precis cardiac map system confirm rx insert cardiac monitor
smartphon compat icm detect arrhythmia advisor hd grid
map cathet creat detail map heart launch
europ confirm rx track cross million ww sale year
quarter launch
mitraclip high profil devic within abt structur heart portfolio estim
ww mitraclip sale million structur heart sale rise anoth
million nearli assum fda approv mitraclip use
patient suffer secondari mitral regurgit believ sale growth
mitraclip sustain anoth year base present associ
panel discuss tct constru compet devic year
enter
busi find place preview could sourc upsid surpris
rhythm manag ww revenu slump year-over-year stage
gradual recoveri previou month declin larg function low-
teen drop pacemak sale categori done well either
past coupl quarter report growth pacemak sale help
leadless pacer micra pull reveal linq icm icd abt manag
point sluggish replac cycl pull forward unit due
batteri issu surfac de novo segment well accord
manag crt-d sale rose low single-digit in-lin market
expect manag narrow guidanc top half
departur past practic rais revenu ep guidanc midway
year result even though compani face tougher comp
signal high degre confid part manag organ cc revenu
growth
current guidanc follow
organ revenu growth increas bp call fx forecast
add bp report growth howev base current level direct
exchang rate currenc might well neutral revenu growth
medic devic establish pharmaceut high single-digit
nutrit mid-singl digit interpret
diagnost mid high single-digit interpret
ep non-gaap increas call
follow result expect narrow guidanc organ revenu growth
non-gaap ep revenu estim
billion impli organ growth ep estim
believ estim organ revenu growth non-gaap ep room
move higher post septemb quarter result currenc howev could move advers
well negat chang estim revenu estim billion
assum neg contribut currenc million
exhibit revenu model
updat estim initi estim
increas price target
host manag non-deal roadshow mid-may meet
took place heel strong underscor breadth depth abt new
product cycl diagnost medic devic segment share compel
attribut strong revenu growth high margin june quarter result
reinforc confid durabl outlook abt key growth franchis alin
mitraclip freestyl libr spinal cord stimul electrophysiolog heartmat name
abt growth could also get boost entri portico
keep factor mind rais estim organ revenu growth
almost bp revenu estim remain unchang billion
howev higher organ growth estim nullifi near ident chang
estim currenc headwind revenu estim assum neg fx
geographi worldwiderevenu revenu growth excl growth excl revenu growth excl growth revenu growth revenu excl revenu incl medic suppli devic
contribut bp roughli bp wors prior estim direct
emerg market currenc move recent suggest fx headwind
could get wors await guidanc topic earn call ep
estim goe consensu impli y/i
growth increas driven higher margin assumpt interest incom
look ahead initi revenu ep estim billion
y/i y/i consensu revenu estim
includ fx contribut estim assum high single-digit growth medic
devic establish pharmaceut mid high single-digit growth diagnost
mid single-digit growth nutrit ep estim impli ep compound-annual-growth-rate
place top-tier large-cap med-tech compani coverag
similar growth profil
less month left believ appropri shift base year
valuat new price target base blend ev/ebitda
multipl ebitda estim billion multipl
use arriv old price target ebitda estim averag
ev/ebitda ntm multipl base consensu estim
impli price-to-earnings multipl ep estim
current trade in-lin discount base ep
estim henc scope abt multipl increas strong
might catalyst reiter outperform rate
exhibit sum-of-the-part valuat share
sum-of-the-part valuat abt five major busi base ebitda estim
yield price target individu ev/ebitda multipl use valuat
establish pharmaceut multipl along ebitda
estim busi give blend ev/ebitda estim consolid
ebitda billion target impli multipl ep estim
share current trade around ep estim price
target basi outperform rate
risk rate price target
face risk typic global diversifi healthcar compani impedi
price target rate includ competit currenc patent litig reimburs
clinic trial risk navig fda prolong econom slump
abbott laboratori one diversifi health care product compani
world product encompass intern brand gener drug devic diagnost
except ep fy dec
